Wednesday, July 8, 2026

Patent intelligence · US

US 11911465

Vaccine compositions and methods of use

granted A61KA61K2039/55511A61K2039/55555A61K2039/70
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 18
Applicant portfolio 11
Patent details — US 11911465
Jurisdiction
US
Status
granted
Grant date
Feb 27, 2024
Expiration
Feb 22, 2044
Claims
12
CPC classes
A61K, A61K2039/55511, A61K2039/55555, A61K2039/70
View on Google Patents ↗

Quick answer

US 11911465 (Vaccine compositions and methods of use) is held by PDS Biotechnology Corporation. Status: granted. Granted Feb 27, 2024. Expires Feb 22, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
12
CPC classes
A61K, A61K2039/55511, A61K2039/55555, A61K2039/70, A61K39/0002, A61K39/0005

More from PDS Biotechnology Corporation

Related pharmaceutical patents in our USPTO index.

  1. US 11911359

    Stimulation of an immune response by cationic lipids

    PDS Biotechnology Corporation · Expires Feb 22, 2044

    granted
  2. US 11904015

    Vaccine compositions and methods of use

    PDS Biotechnology Corporation · Expires Feb 15, 2044

    granted
  3. US 11801257

    Stimulation of an immune response by enantiomers of cationic lipids

    PDS Biotechnology Corporation · Expires Oct 26, 2043

    granted
  4. US 11638753

    Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy

    PDS Biotechnology Corporation · Expires Apr 27, 2043

    granted
  5. US 11612652

    Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy

    PDS Biotechnology Corporation · Expires Mar 23, 2043

    granted
  6. US 11401306

    HPV16 non HLA-restricted t-cell vaccines, compositions and methods of use thereof

    PDS Biotechnology Corporation · Expires Jul 28, 2042

    granted
  7. US 10702541

    Stimulation of an immune response by enantiomers of cationic lipids

    PDS Biotechnology Corporation · Expires Jul 2, 2040

    granted

Frequently asked questions

What is US patent 11911465?

US 11911465 (Vaccine compositions and methods of use) is held by PDS Biotechnology Corporation. Status: granted. Granted Feb 27, 2024. Expires Feb 22, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11911465?

PDS Biotechnology Corporation is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 11 pharmaceutical patents for this assignee.

When does US 11911465 expire?

Our index shows an expiration date of Feb 22, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.